Pancreatic ductal adenocarcinoma (PDAC) is the most common malignant tumor of the pancreas. PDAC is an aggressive and difficult to treat malignant tumor. Complete surgical removal of the tumor remains the only chance of recovery, but 80-90% of patients suffer from a surgically incurable disease at the time of clinical presentation (15). Despite our advanced knowledge on the tumor biology of PDAC, the improvement of diagnosis and management and the rise of centers specializing in the management of patients with PDAC, the prognosis remains surprisingly poor (4, 17). The following overview will discuss the epidemiology and tumor biology of PDAC, as well as important information for patients and family, including diagnosis, treatment, and prognosis. This overview will not discuss cancer that occurs in cystic lesions of the pancreas, nor pancreatic neuroendocrine tumors, as these variants have different biology and prognosis.
Scientific Tracks Abstracts: Cardiovascular Diseases & Diagnosis
Scientific Tracks Abstracts: Cardiovascular Diseases & Diagnosis
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Cancer Science & Therapy
Scientific Tracks Abstracts: Cancer Science & Therapy
Scientific Tracks Abstracts: Cancer Science & Therapy
Keynote: Alternative & Integrative Medicine
Keynote: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Journal of Sports Medicine & Doping Studies
Posters & Accepted Abstracts: Journal of Sports Medicine & Doping Studies
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 